

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**In re application of:** Bruce G. Gold

**Application No.** To be assigned

**Filed:** Herewith

**Confirmation No.** To be assigned

**For:** COMPOSITIONS AND METHODS FOR  
PROMOTING NERVE REGENERATION

**Examiner:** To be assigned

**Art Unit:** 1647

**Attorney Reference No.** 899-66834

CERTIFICATE OF EXPRESS MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as Express Mail Label No. EV339203016USI in an envelope addressed to: MAIL STOP PATENT APPLICATION, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Agent  
for Applicant(s)

Date Mailed September 4, 2003

MAIL STOP PATENT APPLICATION  
COMMISSIONER FOR PATENTS  
P.O. BOX 1450  
ALEXANDRIA, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**  
**FOR CONTINUING APPLICATIONS**

Listed on the accompanying form PTO-1449 are several English-language documents.

Applicant respectfully requests that such documents be listed as references cited on the issued patent.

The present application relies upon U.S. Patent Application No. 09/825,243, which was filed April 2, 2001, for an earlier filing date under 35 U.S.C. § 120. Furthermore, documents listed on the accompanying form PTO-1449 were disclosed to or cited by the Patent Office in the earlier U.S. application.


Copies of the documents listed on the accompanying form PTO-1449 that were cited by applicant in the earlier application need not be sent to the Patent Office pursuant to 37 C.F.R. § 1.98. However, applicant will furnish the Patent Office with such copies upon request.

Please charge any additional fees that may be required in connection with filing this Information Disclosure Statement, or credit any overpayment, to Deposit Account No. 02-4550. A duplicate copy of the transmittal sheet for this Information Disclosure Statement is enclosed.

The filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in Rule 56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By   
Susan Alpert Siegel, Ph.D.  
Registration No. 43,121

One World Trade Center, Suite 1600  
121 S.W. Salmon Street  
Portland, Oregon 97204  
Telephone: (503) 226-7391  
Facsimile: (503) 228-9446

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	<b>Attorney Docket Number</b>	899-66834
	<b>Application Number</b>	To be assigned
	<b>Filed</b>	Herewith
	<b>First Named Inventor</b>	Gold
	<b>Art Unit</b>	1647
	<b>Examiner Name</b>	To be assigned

**U.S. PATENT DOCUMENTS**

Examiner's Initials*	Cite No. (optional)	Number	Date	Name
		5,026,381	25 June 1991	Li
		5,192,773	9 Mar 1993	Armistead et al.
		5,330,993	19 July 1994	Armistead et al.
		5,516,797	14 May 1996	Armistead et al.
		5,525,523	11 June 1996	Soldin
		5,543,423	6 Aug 1996	Zelle et al.
		5,612,350	18 Mar 1997	Or et al.
		5,614,547	25 Mar 1997	Hamilton et al.
		5,620,971	15 Aug 1997	Armistead et al.
		5,622,970	22 Apr 1997	Armistead et al.
		5,639,592	17 June 1997	Evans et al.
		5,654,332	5 Aug 1997	Armistead
		5,780,484	14 July 1998	Zelle et al.
		5,811,434	22 Sep 1998	Zelle et al.
		5,840,736	24 Nov 1998	Zelle et al.
		5,968,921	19 Oct 1999	Gold
		6,037,370	14 Mar 2000	Armistead

EXAMINER SIGNATURE:	DATE CONSIDERED:
<p>* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

**FOREIGN PATENT DOCUMENTS**

Examiner's Initials*	Cite No. (optional)	Number	Date	Country
		WO 92/04370	19 Mar 1992	PCT
		WO 92/19593	12 Nov 1992	PCT
		WO 92/19745	12 Nov 1992	PCT
		WO 92/21313	10 Dec 1992	PCT
		WO 93/07269	15 Apr 1993	PCT
		WO 93/23548	25 Nov 1993	PCT
		WO 96/40140	19 Dec 1996	PCT
		WO 96/40633	19 Dec 1996	PCT
		WO 97/18828	29 May 1997	PCT
		WO 98/20891	22 May 1998	PCT
		WO 98/20892	22 May 1998	PCT
		WO 98/20893	22 May 1998	PCT
		WO 99/21552	6 May 1999	PCT

**OTHER DOCUMENTS**

Examiner's Initials*	Cite No. (optional)	
		Abstract, <i>J. Biol. Chem.</i> , 252(1):308-317, 1977.
		Abstract, <i>Biochem.</i> , 31(9):2482-91, 1992.
		Abstract, <i>Mol. Endocrinol.</i> , 7(11):1418-29, 1993.
		Abstract, <i>J. Clin. Investigation</i> , 99(6):1217-23, 1997.
		Armistead et al., Design, Synthesis and Structure of Non-macrocyclic Inhibitors of FKBP12, the Major Binding Protein for the Immunosuppressant FK506, <i>Acta Cryst D</i> 51:522-528 (1995).
		Bozzo et al., <i>Exp. Cell Res.</i> , 214:313-22, 1994.

EXAMINER  
SIGNATURE:

DATE  
CONSIDERED:

\* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

		Buttemeyer et al., <i>Transpl. Proc.</i> , 27:1877-1878, 1995.
		Buttemeyer et al., <i>Ann. Plast. Surg.</i> , 35:396-401, 1995.
		Czar et al., Geldanamycin, a Heat Shock Protein 90-Binding Benzoquinone Ansamycin, Inhibits Steroid-Dependent Translocation of the Glucocorticoid Receptor from the Cytoplasm to the Nucleus, <i>Biochemistry</i> 36:7776-7785 (1997).
		David et al., <i>Science</i> , 214:931-33, 1991.
		Jackowski et al., <i>Brit. J. Neurosurg.</i> , 9:303-317, 1995.
		Lee et al., Peripheral Nerve Injury and Repair, <i>J. Am. Acad. Orthop. Surg.</i> , 8(4):243-252, 2000
		Miller et al., <i>J. of Neurochemistry</i> , 60:2134-44, 1993.
		Owens-Grillo et al., The Cyclosporin A-binding Immunophilin CyP-40 and the FK506-binding Immunophilin hsp56 Bind to a Common Site on hsp90 and Exist in Independent Cytosolic Heterocomplexes with the Untransformed Glucocorticoid Receptor, <i>The Journal of Biological Chemistry</i> 270:20479-20484 (1995).
		Owens-Grillo et al., Binding of Immunophilins to the 90 kDa Heat Shock Protein (hsp90) via a Tetratricopeptide Repeat Domain Is a Conserved Protein Interaction in Plants, <i>Biochemistry</i> 35:15249-15255 (1996).
		Pratt, W.B., The Role of the hsp90-based Chaperone System in Signal Transduction by Nuclear Receptors and Receptors Signaling Via MAP Kinase, <i>Annu. Rev. Pharmacol. Toxicol.</i> 37:297-326 (1997).
		Pratt, W.B. and Toft, D.O., Steroid Receptor Interactions with Heat Shock Protein and Immunophilin Chaperones, <i>Endocrine Reviews</i> 18:306-360 (1997).
		Preis et al., <i>Cancer Res.</i> , 48:6530-34, 1988.
		Ratajczak, T. and Carrello, A. Cyclophilin 40 (CyP-40), Mapping of Its hsp90 Binding Domain and Evidence That FKBP52 Competes with CyP-40 for hsp90 Binding, <i>The Journal of Biological Chemistry</i> , 271:2961-2965 (1996).
		Sanchez, E.R. and Ning, Y-M., Immunophilins, Heat Shock Proteins, and Glucocorticoid Receptor Actions <i>in Vivo</i> , <i>Methods</i> 9:188-200 (1996).
		Schawab, Repairing the Injured Spinal Cord, <i>Science</i> , 295:1029-1031, 8 Feb. 2002

EXAMINER SIGNATURE:	DATE CONSIDERED:
<p>* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

		Segnitz and Gehring, The Function of Steroid Hormone Receptors is Inhibited by the hsp90-specific Compound Geldanamycin, <i>The Journal of Biological Chemistry</i> 272:18694-18701 (1997).
		Smith et al., Progesterone Receptor Structure and Function Altered by Geldanamycin, an hsp90-Binding Agent, <i>Molecular and Cellular Biology</i> 15:6804-6812 (1995).
		Smith, <i>Elements of Molec. Neurobio.</i> , 2 <sup>nd</sup> ed., p. 141-142.
		Stancato et al., The hsp90-binding Antibiotic Geldanamycin Decreases Raf Levels and Epidermal Growth Factor Signaling without Disrupting Formation of Signaling Complexes or Reducing the Specific Enzymatic Activity of Raf Kinase, <i>The Journal of Biological Chemistry</i> 272:4013-4020 (1997).
		Stebbins et al., Crystal Structure of an Hsp90-Geldanamycin Complex: Targeting of a Protein Chaperone by an Antitumor Agent, <i>Cell</i> 89:239-250 (1997).
		Tanzer L. and Jones K.J., Gonadal Steroid Regulation of Hamster Facial Nerve Regulation: Effects of Dihydrotestosterone and Estradiol, <i>Experimental Neurology</i> 146:258-264 (1997).
		Wells et al., <i>Exp. Neurol.</i> , 146:395-402, 1997.
		Whitesell et al., <i>Cancer Res.</i> , 52:1721-28, 1992.
		Whitesell et al., Inhibition of Heat Shock Protein HSP90-pp60 <sup>v-src</sup> Heteroprotein Complex Formation by Benzoquinone Ansamycins: Essential Role for Stress Proteins in Oncogenic Transformation, <i>Proc. Natl. Acad. Sci. USA</i> 91:8324-8328 (1994).

EXAMINER SIGNATURE:	DATE CONSIDERED:
<p>* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	